Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.70
Bid: 28.10
Ask: 30.70
Change: 1.90 (6.60%)
Spread: 2.60 (9.253%)
Open: 28.10
High: 30.70
Low: 28.10
Prev. Close: 28.80
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update

20 Mar 2017 07:00

RNS Number : 8764Z
EKF Diagnostics Holdings PLC
20 March 2017
 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

Update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the following update for shareholders.

 

The Directors are currently evaluating plans under which they would split the Company into two separate companies based on the business divisions, namely Point of Care and Lab Diagnostics. Whilst both these business divisions are valuable in their own right, the Directors consider that separating the companies out represents a better route for shareholders and one under which they are more likely to achieve a fair reflection of the value of each separate business.

 

However, based on tax advice received by the Company, it is the Directors' understanding that US federal income tax chargeable on any gain associated with the divestiture of the business could be significant. In order to mitigate these potentially adverse tax effects, the distribution needs to qualify as a 'tax-free spinoff'. There are numerous requirements in order to achieve this treatment, including that no acquisition of 50% or more of the shares in either the Company (i.e. the business that remains following the divestiture) or the newly separated company may take place within two years of the separation. Accordingly, the articles of association of the two separate companies would be amended so as to include a prohibition of the sale of 50% or more of the shares in the companies without the consent of their directors.

 

The implementation of the above proposal is envisaged to include a cancellation of the Company's shares from trading on AIM following which it is the Directors current intention to seek a listing of the shares of both companies on a market to be determined.

 

The Directors are sympathetic to individual investors' requirements and therefore in order to provide those shareholders that do not wish to wait for the completion of the restructuring and subsequent potential sale of the two businesses with an exit, the Company is evaluating the possibility of a share buyback offer to shareholders. This share buyback offer would, if completed, be prior to the commencement of the separation and would be at a price of 21.5p per share.

 

There can of course be no guarantee that the above proposals, including any share buyback, will be capable of being completed in the manner currently anticipated. Further announcements will be made at the appropriate time

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Alex Price / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDGCGDXRXBBGRC
Date   Source Headline
20th May 20147:01 amRNSAGM Statement
20th May 20147:00 amRNSSelah to provide Women's Health testing services
19th May 20143:13 pmRNSHolding(s) in Company - Replacement
16th May 20144:35 pmRNSHolding(s) in Company
15th May 20147:00 amRNSDirector/PDMR Shareholding
8th May 20141:10 pmRNSDirector/PDMR Shareholding
7th May 20147:00 amRNSSelah update
30th Apr 20147:01 amRNSHolding(s) in Company
23rd Apr 20144:46 pmRNSHolding(s) in Company
23rd Apr 20143:33 pmRNSHolding(s) in Company
17th Apr 20141:13 pmRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSInvestor Teach-In
11th Apr 201411:33 amRNSResults of General Meeting and Total Voting Rights
10th Apr 20149:33 amRNSResult of Offer
31st Mar 20144:46 pmRNSDirector Resignation
31st Mar 201410:01 amRNSHolding(s) in Company
26th Mar 20144:18 pmRNSHolding(s) in Company
24th Mar 20147:00 amRNSHolding(s) in Company Replacement
20th Mar 201411:26 amRNSResult of the Placing
20th Mar 20147:00 amRNSProposed Acquisitions, Placing & Offer
12th Mar 20147:00 amRNSAcquisition of Separation Technology, Inc.
4th Mar 201411:16 amRNSTransfer of production
26th Feb 20147:00 amRNSFinal Results
18th Feb 20147:00 amRNSQuo-Lab registration in Mexico
17th Feb 20147:00 amRNSNotice of Results
28th Jan 201412:21 pmRNSAdditional Listing
27th Jan 20147:00 amRNSYear end trading update
24th Jan 20147:00 amRNSHolding(s) in Company
20th Jan 20147:00 amRNSPointMan enriches low-level mutations from blood
19th Nov 20137:00 amRNSAcute Kidney Injury marker development
4th Nov 20137:00 amRNSNew PointManT DNA enrichment products launched
30th Oct 20133:10 pmRNSHolding(s) in Company
8th Oct 20138:25 amRNSHolding(s) in Company
3rd Oct 20139:03 amRNSChange of Registered Office
25th Sep 201311:34 amRNSHolding(s) in Company
19th Sep 20137:28 amRNSInvestor Results Briefing
16th Sep 20137:00 amRNSInterim Results
14th Aug 20137:00 amRNSInvestor Teach-In
1st Aug 20137:00 amRNSTrading update
25th Jul 20137:00 amRNSInvestor Teach-In
23rd Jul 20137:00 amRNSSenior management update
4th Jul 201312:09 pmRNSHolding(s) in Company
26th Jun 20135:43 pmRNSAnalyst & Investor Teach-In
18th Jun 201310:17 amRNSDirector Share Transfer
11th Jun 20133:52 pmRNSAmendment to Long-Term Incentive Plan
15th May 20134:34 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement
13th May 20137:00 amRNSFirst PointMan DNA enrichment products launched
15th Apr 20131:34 pmRNSPublication of Annual Report & Notice of AGM
18th Mar 20137:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.